Company profile

E. Kevin Hrusovsky
Incorporated in
Fiscal year end

QTRX stock data

FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings
Securities sold
Number of investors


8 Nov 19
22 Feb 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 14.94M 13.54M 12.34M 10.88M
Net income -9.87M -10.56M -9.41M -9.33M
Net profit margin -66.05% -78.04% -76.23% -85.81%
Operating income -10.24M -10.51M -9.36M -9.41M
Net change in cash 41.3M 38.05M 32.15M -49.6M
Cash on hand 113.33M 72.03M 33.97M 1.82M
Cost of revenue 7.91M 6.61M 6.33M 5.67M
Annual (USD) Dec 18 Dec 17 Dec 16
Revenue 37.63M 22.87M 17.59M
Net income -31.54M -27.02M -23.17M
Net profit margin -83.80% -118% -132%
Operating income -31.55M -26.01M -21.71M
Net change in cash 321K -28.17M
Cash on hand 1.82M 1.5M 29.67M
Cost of revenue 19.68M 12.89M 9.84M

Financial data from Quanterix earnings reports

71.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 84 89 -5.6%
Opened positions 8 16 -50.0%
Closed positions 13 16 -18.8%
Increased positions 36 49 -26.5%
Reduced positions 22 11 +100.0%
13F shares
Current Prev Q Change
Total value 502.95M 415.31M +21.1%
Total shares 19.76M 18.91M +4.5%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Gilder Gagnon Howe & Co 3.34M $78.99M -2.3%
Bain Capital Venture Investors 2.14M $50.48M 0.0%
N Price T Rowe Associates 1.44M $34.13M -11.4%
MCQEF Macquarie 1.34M $31.61M +18.8%
BLK BlackRock 1.2M $28.44M -0.3%
AMP Ameriprise Financial 1.17M $27.65M +9.6%
Vanguard 922.43K $21.8M +22.1%
FMR 888.22K $20.99M +24.0%
Ashford Capital Management 621.51K $14.69M +36.3%
Millennium Management 523.71K $12.38M +9.5%
Largest transactions
Shares Bought/sold Change
Portolan Capital Management 371.34K +261.09K +236.8%
MCQEF Macquarie 1.34M +211.95K +18.8%
N Price T Rowe Associates 1.44M -185.25K -11.4%
FMR 888.22K +171.84K +24.0%
Vanguard 922.43K +167.09K +22.1%
Ashford Capital Management 621.51K +165.37K +36.3%
Summit Partners Public Asset Management 0 -150K EXIT
WINTON 145.87K +145.87K NEW
Polar Asset Management Partners 0 -110.79K EXIT
AMP Ameriprise Financial 1.17M +102.7K +9.6%

Financial report summary

Management Discussion
  • Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and our audited financial statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results, performance or experience could differ materially from what is indicated by any forward-looking statement due to various important factors, risks and uncertainties, including, but not limited to, those set forth under “Special Note Regarding Forward-Looking Statements” included elsewhere in this quarterly report or under “Risk Factors” in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2018 or other filings that we make with the SEC.
  • We are a life sciences company that has developed next generation, ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Our platforms are based on our proprietary digital “Simoa” detection technology. Our Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allow researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations and have been discovered using technologies such as mass spectrometry. These capabilities provide our customers with insight into the role of protein biomarkers in human health that has not been possible with other existing technologies and enable researchers to unlock unique insights into the continuum between health and disease. We believe this greater insight will enable the development of novel therapies and diagnostics and facilitate a paradigm shift in healthcare from an emphasis on treatment to a focus on earlier detection, monitoring, prognosis and, ultimately, prevention. We are currently focusing on protein detection, which we believe is an area of significant unmet need and where we have significant competitive advantages. However, in addition to enabling new applications and insights in protein analysis, we are also developing our Simoa bead-based technology to detect nucleic acids in biological samples.
Content analysis ?
H.S. sophomore Avg
New words: ahead, amortizable, efficiency, enacted, exempt, foreign, gain, jurisdiction, necessarily, neurofilament, perspective, preliminarily, promulgated, provisional, rest, Section, SVB, technical, thereunder, translated, Translation, Ume, uncertain, underwritten, upgraded, user, version
Removed: assurance, throughput, trading, unrestricted